Table 1 Key characteristics of the patient cohort
From: MYCN protein stability is a better prognostic indicator in neuroblastoma
Characteristics | FISH−(n = 25) | FISH+(n = 28) | Total(n = 53) |
|---|---|---|---|
IHC (MYCN) | |||
 0 | 20(37.74%) | 4(7.55%) | 24(45.28%) |
 1 ~ 8 | 4(7.55%) | 6(11.32%) | 10(18.87%) |
 ≥9 | 1(1.89%) | 18(33.96%) | 19(35.85%) |
Age | |||
 > 18 m | 13(24.53%) | 19(35.85%) | 32(60.38%) |
 ≤18 m | 12(22.64%) | 9(16.98%) | 21(39.62%) |
Stage | |||
 Stage 1 | 5(9.43%) | 2(3.77%) | 7(13.21%) |
 Stage 2 | 2(3.77%) | 0(0.0e+ 0%) | 2(3.77%) |
 Stage 3 | 8(15.10%) | 12(22.64%) | 20(37.74%) |
 Stage 4 | 7(13.21%) | 14(26.42%) | 21(39.62%) |
 Stage 4S | 3(5.66%) | 0(0.0e+ 0%) | 3(5.66%) |
Risk | |||
 Low | 6(11.32%) | 0(0.0e+ 0%) | 6(11.32%) |
 Med | 7(13.21%) | 3(5.66%) | 10(18.87%) |
 High | 5(9.43%) | 14(26.42%) | 19(35.85%) |
 Very High | 7(13.21%) | 11(20.75%) | 18(33.96%) |
Complete primary tumor resection | |||
 No | 5(9.43%) | 6(11.32%) | 11(20.75%) |
 Yes | 20(37.74%) | 22(41.51%) | 42(79.25%) |
Autologous stem cell transplantation | |||
 No | 21(39.62%) | 26(49.06%) | 47(88.68%) |
 Yes | 4(7.55%) | 2(3.77%) | 6(11.32%) |
External Radiotherapy | |||
 No | 18(33.96%) | 13(24.53%) | 31(58.49%) |
 Yes | 7(13.21%) | 15(28.30%) | 22(41.51%) |
Event | |||
 No | 17(32.08%) | 19(35.85%) | 36(67.92%) |
 Yes | 8(15.09%) | 9(16.98%) | 17(32.08%) |
EFS months | |||
 Median [min-max] | 58.43[4.70,109.73] | 13.52[0.33,74.17] | 28.00[0.33,109.73] |
Follow up status | |||
 CR | 17(32.08%) | 21(39.62%) | 38(71.70%) |
 Death | 8(15.09%) | 7(13.21%) | 15(28.30%) |
OS months | |||
 Median [min-max] | 58.43[5.93,109.73] | 16.73[0.33,74.17] | 30.47[0.33,109.73] |